In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Valeant pays €314mm in cash for AB Sanitas

Executive Summary

Keeping in line with its goal to acquire five ex-US companies before the end of 2011, Valeant Pharmaceuticals International Inc. (neurology and dermatology therapies) has agreed to buy publicly traded Lithuanian generic drug maker AB Sanitas for €314mm ($442mm) in cash and it will assume €50mm in debt.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies